Truth in science.
Transformation in medicine.
At Vera Therapeutics, we pursue truth in science to transform medicine in autoimmune diseases, starting with the kidney.
Rigorous science
We focus on upstream immune pathways that drive disease, asking hard questions and following the evidence.
Patient-centered
We listen closely to patients and caregivers, so their experiences help shape how we approach disease, not just how we measure it.
Designed with intention
Vera Therapeutics was designed to think long term, with independent and disciplined focus on the work that meaningful progress requires.
OUR FOCUS
Committed to IgA nephropathy
We are deeply focused on IgA nephropathy, where the immune drivers of disease remain largely unaddressed and patient need is high.
FEATURED news
November 5, 2026
Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
- TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3 million of net product revenue in Q3.
- ORIGIN 3 final efficacy analysis demonstrated stabilization of kidney function and a 76% reduction in risk of composite kidney disease progression versus placebo through two years; data was presented as a late-breaking oral presentation at the opening plenary session at ASN Kidney Week 2026 with a simultaneous publication in The New England Journal of Medicine.
- Completed supplemental Biologics License Application (sBLA) submission to the FDA for full approval of TRUTAKNA in adults with primary IgAN.
- Management to host a live investor webcast at 4:30 p.m. ET on November 5, 2026.
Built on truth, driven by science
We challenge long-standing assumptions in nephrology by combining rigorous science with a deep respect for the lived experience to turn discovery into meaningful progress.
Patient stories
We listen to the lived experiences of people affected by disease. Their perspectives help shape how we pursue new approaches and measure progress.
Working at Vera Therapeutics
We move with purpose, uphold scientific rigor, and value the perspectives that help us see the whole human experience behind complex disease.
Investor & Media Relations
Access our investor and media relations center for company news, financial information, and resources for analysts and journalists.